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ABSTRACT
Tumor cells are notorious for their ability to escape immune surveillance, but
developments in the understanding of the tumor microenvironment and how the immune
system can be re-activated in tumors have had significant clinical impact. Commercially
available and experimental methods such as adoptive cellular therapy, cytokine
stimulation, and immune checkpoint blockade are promising immunotherapies for a
variety of cancers, including solid tumors and hematological malignancies. However,
induction of persistent, long-term anti-tumor immunity after initial treatment is infamously
difficult. As a result, scientists are searching for new approaches to improve established
immunotherapies. By employing combination treatments or enhancing the functionality
of cellular products prior to infusion, patients may experience better clinical outcomes
through the development of more effective immunotherapies. This thesis reviews the
function of the immune system in the tumor microenvironment and discusses how this
knowledge is used within the field of tumor immunology to develop and enhance
immunotherapy models.

xii

CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Surgery, chemotherapy, and radiotherapy are traditionally considered standard
treatments of care for cancer patients. However, the immune system has been used to
establish new and effective methods to treat cancer. The field of tumor immunology
seeks to understand the relationship between the immune system and cancer.
Normally, the immune system functions by identifying and eliminating pathogens to
protect the body from disease. However, cancer cells are notorious for their ability to
escape immune recognition. By acknowledging that the immune system’s diminished
functionality in cancer can drive tumor progression, scientists have been able to develop
novel cancer immunotherapies, in which the immune system is stimulated and used to
treat cancer. Although humans possess tumor-reactive T cells that can lead to antitumor immunity, host anti-tumor responses are usually too weak to induce tumor
regression. The goal of cancer immunotherapy is to activate the immune system and
generate a response that is clinically strong enough to induce regression. Research has
been able to pinpoint issues within immune pathways in tumors to enhance the immune
system in a way that encourages your immune cells to more efficiently kill tumor cells.
There are many immunotherapies available to treat cancer. Methods to treat
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cancer via immune system include cytokine administration, cancer vaccines, therapeutic
monoclonal antibodies, immune checkpoint inhibitors, and adoptive cell transfer (ACT).1
Figure 1 demonstrates different methods of cancer immunotherapy and common
examples of each. This diagram is not exhaustive, and there are many other therapies
that fall under each subtype of cancer immunotherapy.

Figure 1. Types of Cancer Immunotherapy. Cancer immunotherapies are used to
manipulate immune functions to activate the immune system in the presence of cancer.
Common examples of each type of therapy are given, although there are more therapy
options that are not listed in this diagram specifically.
T cells play a major role in many immunotherapy strategies, as T cells are an extremely
important cell population for immune system function.2 Tumor-reactive T cells have
been discovered in the peripheral blood, secondary lymphoid organs, and tumor lesions
of tumor-bearing hosts.3 Although their presence is very rare, these T cells are able to
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target tumor cells and can mediate tumor regression.4 Because the research projects I
pursued during my Master’s program focused on gene modified T cells and their ability
to target tumors, this thesis will primarily review tumor recognition by T cells, the impact
of the tumor microenvironment on T cell function, and how genetically modified T cells
can be used for cancer therapy.
Cancer Biology
Cancer is an overarching term used to refer to a large group of diseases that
originate from within host tissue and can exhibit similar biological characteristics. It is
often considered an age-related disease because risk increases with increasing age.5
This is because as you get older, your cells accrue mutations, and those mutations can
prohibit your cells from functioning normally.6 Mutations in specific types of genes,
either oncogenes or tumor suppressor genes, can initiate oncogenesis.7,8 Oncogenes
are genes that are able to drive transformation of normal cells into tumor cells, typically
by stimulating cell growth and survival.8,9 The discovery of proto-oncogenes introduced
the idea that cells that have acquired activating mutations can transform normal cells to
cancer cells.8,10 On the other hand, tumor suppressor genes are those that regulate cell
growth and promote DNA repair.9 Knudson first suggested the existence of tumor
suppressor genes when he introduced his “2-hit” model.11 He discovered that although
both copies of a tumor suppressor gene need to be lost in order to develop an
oncogenic phenotype, loss of one gene copy usually is followed by the loss of the
second copy, resulting in tumorigenesis.11 When a cell accrues mutations that result in
the loss-of-function in tumor suppressor genes, or gain-of-function in oncogenes, or
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both, tumorigenesis can occur as a consequence of the cellular dysfunction and
genomic instability that the mutation causes.9,12,13 Figure 2 demonstrates an example of
normal cell transformation into a cancer cell after the accrual of dysregulating mutations.

Figure 2. Mutations Drive Oncogenesis. The accrual of mutations in normal cells is
largely credited for the formation of tumors. Functional tumor suppressor and
oncogenes regulate normal functions within the cell. Mutations in those genes introduce
dysfunctional cellular mechanisms, and the accrual of mutations in oncogenes drive
dysfunctional cells towards survival while mutations in tumor suppressor genes prohibit
those cells from repairing the mutations or inducing growth arrest. In this example,
transformation begins with a mutation in a tumor suppressor gene, but the process of
mutation accrual and transformation doesn’t always occur in this particular order.
Adapted from “Building a Model of Tumorigenesis: A small group activity for a cancer
biology/cell biology course,” by L. Wright, 2015, CourseSource, Web.
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In this example, an initial mutation in a tumor suppressor gene allows the cell to divide
rapidly. Then, a secondary mutation in a DNA repair gene prohibits those cells from
repairing their mutations. This allows subsequent aberrant mutations to occur, including
mutations in oncogenes that promote cell survival and inhibit cell death. Because there
are so many genes involved in the regulation of cellular processes, there is a nearly
endless number of genes whose mutations can be held responsible for tumor
development.14 Cancer cells consistently mutate when they divide, which results in
vastly heterogenous tumors.15 Along with the accumulation of genetic mutations, certain
viral infections have been identified as drivers of oncogenesis, as certain viruses are
able to evade immune recognition and can introduce mutations in the genome.16 Human
Papilloma Virus (HPV) and Epstein-Barr Virus (EBV) infections are strongly linked to the
onset of many different malignancies, including most notably cervical cancer and
Burkitt’s lymphoma.16 Although cancer cells are known to be extremely heterogenous,
there are a few “hallmarks” that cancer cells display.17 These behaviors include
promoting cell growth, evading growth arrest, avoiding apoptosis, manipulating cell
metabolism, replicating an infinite number of times, promoting angiogenesis, avoiding
immune destruction, and invading other tissues to form metastases.17 It is clear that the
amalgamation of these behaviors results in cells that are driving towards cell survival
and growth, while simultaneously prohibiting regulatory and inhibitory mechanisms. An
important distinction here is that these hallmarks of cancer are features shared among
malignant tumors only; benign tumors do not possess all of these characteristics.17
Although tumor cells develop via gene dysregulation due to mutations and viral
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oncogenes, and those genetic changes often lead to the development of sophisticated
survival mechanisms, cancer cells also employ defense mechanisms through which
tumors are able to evade detection by or suppress the immune system. Strong immune
suppression induced by tumors often explains why immune cells struggle to illicit strong
responses against cancer, as immune cell functionality is severely diminished within the
tumor microenvironment.
Tumor Immunology
New research into the tumor immune microenvironment has shed light on the
specific systems that tumors employ to inhibit immune responses.18,19 Although it is
known that tumors can be immunogenic, tumor cells exploit a number of mechanisms to
evade detection by the immune system.20,21 For example, tumor cells produce
transforming growth factor b (TGF-b), tumor necrosis factor a (TNF-a), and chemokines
that attract Tregs to the tumor microenvironment, resulting in immunosuppression within
the tumor.22 Myeloid-derived suppressor cells are also known to drive immune
suppression, and tend to demonstrate increased circulation within the tumor
microenvironment.22,23 Figure 3 depicts a few immune suppressive mechanisms within
the tumor microenvironment that prohibit efficient immune cell functionality. Tumor cells
also have the ability to manipulate the antigen presentation pathway and prohibit
antigen presentation on the surface of their cells, making it impossible for T cells to
recognize them.22,24 These defense mechanisms allow tumors to invade other tissues
and metastasize as they are essentially invisible to the body’s disease recognition
systems.22
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Figure 3. Immune Suppression Induced by Tumors. Tumors promote immune
suppressive environments by secreting regulatory cytokines like TGF-b, TNF-a, and
other chemokines to attract suppressor cells such as MDSCs or Tregs to the tumor.
Those molecules and cells can directly suppress immune cells and prohibit their
activation. Adapted from “Clinical Research in Tumor Immunology: Tumor Immunity,”
Graduate School of Medicine, Osaka University, Web.
The inhospitable environment that tumor cells produce limit immune cell functionality,
survival, and trafficking within the tumor environment.25 However, developments in the
understanding of the tumor microenvironment and how the immune system can be reactivated in tumors have had significant clinical impact. This knowledge has given
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scientists’ confidence in the idea that the immune system can be stimulated in such a
way that a patient’s immune system will be able to effectively target and destroy tumor
cells. The discipline of immunotherapy has developed as a result of the promise that lies
in taking advantage of the immune system to treat cancer. However, the field of
immunotherapy has only been able to take hold and elucidate new methods of cancer
treatment by thoroughly understanding the normal processes of immune system
recognition and activation.
Cellular Immune Responses
The immune system’s purpose is to protect the body against pathogens which
cause diseases. The host immune system is incredibly complex and involves a massive
network of cells, proteins, and processes that work together to not only fight pathogens
like viruses and bacteria, but to also prevent repeated infections.26,27 Antigens are
molecules that are recognized by the immune system that can potentially illicit strong
immune responses. However, not all antigens are capable of activating the immune
system. Antigenic molecules are able to be recognized by and bind to immune cells, but
only immunogenic antigens are capable of inducing an immune response through that
interaction.27 In other words, immunogens are antigens, but not all antigens are
immunogenic.27 Antigens that originate from the host are called self-antigens, whereas
non-self antigens are derived from foreign, potentially harmful substances.28 Selfantigens are also considered shared antigens, as they are expressed on both tumor and
normal cells.29 One exception are mutated self-antigens or neoantigens which are
specific to individual tumors, making them patient specific.29 The primary goal of the
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immune system is to seek and destroy non-self antigens.30 Immune cells operate by
surveilling the cells in your body and rely on their ability to accurately distinguish self
versus non-self antigens.30 Immune cells that recognize self-antigens are normally
eliminated during development, but when those cells escape, autoimmunity can
develop.31 Therefore, assuming that an immune cell developed correctly, it should be
able to recognize antigen. When immune cells recognize a foreign antigen, there are
two main responses, the innate response and the adaptive response.32 The cell types
that play a role in innate immunity are responsible for the initial and rapid response to
foreign bodies.32,33 Although the cells in the innate response are able to utilize receptors
to recognize cells, they cannot distinguish self from non-self, and instead recognize
stress proteins, and as a result their reactivity is broad and non-specific.34 The adaptive
immune response is more specialized as these cells are antigen-specific.33 Adaptive
response cells like T and B lymphocytes are able to recognize and target specific
pathogens and develop long-term memory.32 Because T and B cells possess unique
receptors on their surface that can recognize specific antigens, their functional
mechanisms are more specialized than the innate responding cells.32 However, in order
for immune cells to find and recognize antigens expressed on cells, antigens must first
be properly presented to the immune system. Antigen processing allows antigens to be
cleaved and prepared for presentation to T lymphocytes via peptides on MHC
molecules.
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Antigen Processing and Presentation
Dendritic cells play a critical role in immune responses and are a subset of cells
known as antigen-presenting cells (APCs). They are able to process antigens internally,
then migrate and present those antigens to T cells to induce an immune response.35
Antigens are processed into short peptides that are loaded onto major histocompatibility
complex (MHC) molecules presented to T cells.36 Peptides are usually around 8-11
amino acids in length for class I MHC, while class II peptides can be longer.37,38 There
are two primary classes of MHC molecules, class I and class II, and the processing
mechanism that antigens undergo in order to be expressed on MHC class I molecules is
different from MHC class II.
Antigens encoded endogenously by the APC are processed and loaded onto
MHC class I molecules then presented to CD8+ T cells whereas exogenously encoded
antigens are internalized by APCs, processed, and loaded onto MHC class II molecules
then presented to CD4+ T cells.36 As shown for the MHC class I processing pathway in
Figure 4A, internally produced antigens are first degraded into peptides by LMP2 and
LMP7 components in proteasomes within the cytoplasm.39 Then, TAP1 and TAP2 pump
those peptides into the endoplasmic reticulum (ER), and it is within the ER that the
processed antigenic peptide molecules are combined with MHC class I heavy chains
and β2-microglobulin (b2M) to form a mature MHC class I molecule which is transported
to the surface of the APC.39 MHC class I molecules are expressed ubiquitously, and
more specifically, on all nucleated cells.40 However, expression of class I MHC is not
consistent across all cell types.41
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Figure 4. Antigen Processing. Cellular processing mechanisms of antigens in the
MHC class I A) and class II B) pathways. A) Endogenous antigens are processed in
proteasomes into antigenic peptides that are pumped into the endoplasmic reticulum by
TAP1/2, where the peptide is loaded on MHC class I molecules. Mature class I MHC
molecules are transported to the cell surface where they present intracellular peptide
antigens to CD8 T cells. B) Exogenous antigens are endocytosed and processed into
peptides via proteolysis, and the peptides are transported into an endocytic
compartment where they are loaded onto MHC class II molecules. Mature class II MHC
molecules are transported to the cell surface to present extracellular peptide antigens to
CD4 T cells. Adapted from “NLRC5: a key regulator of MHC class I-dependent immune
responses,” by K. Kobayashi, 2012, Nature Reviews Immunology, Vol. 12, 813-820.
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For example, cells within the central nervous system demonstrate reduced MHC class I
expression, likely to minimize the probability of dangerous inflammation in critical
organs, like the brain.41 On the other hand, MHC class II expression and antigen
processing differ significantly from MHC class I.
Antigens presented on MHC class II molecules are expressed on APCs, like
dendritic cells, macrophages, and B cells.40 The class II MHC processing mechanism
differs from the class I processing mechanism, as demonstrated in Figure 4B. MHC
class II subunits are first synthesized in the ER and loaded with an invariant chain. Then
they’re transported to an endocytic compartment where the invariant chain is cleaved by
cathepsins into class II-associated invariant chain peptide (CLIP); at the same time,
exogenous antigens are endocytosed and processed into peptides via proteolysis in
endosomes, then transported into the endocytic compartment with the MHC II
molecules.42 In the endocytic compartment, the antigenic peptide replaces the CLIP
molecule, and the entire MHC/peptide complex is transported to the surface of the
cell.42 However, these two primary pathways of antigen presentation are
not mutually exclusive. Cross presentation is a process in which both pathways merge
because exogenous antigens can be presented to CD8+ T cells via MHC class I
molecules.43 Successful cross presentation plays a large role in the onset of long-term
anti-tumor immunity. Research has been focused on understanding tumor antigen
presentation and how that knowledge can be used in cancer treatment. CD8+ T cells
induce cytotoxic responses and form memory cells, so when they target tumor cells,
there is a stronger probability that anti-tumor immunity will develop and persist.44
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Furthermore, dysfunctional antigen presentation prohibits T cells from recognizing those
cells. Therefore, once peptides are successfully presented on the surface of APCs, T
cell receptors (TCRs) can interact with them and initiate T cell activation. There are
various distinct subtypes of T cells that depend on the proper presentation of antigens,
the largest populations of which include CD8+, CD4+, and T regulatory cells.
T Cell Biology
T Cell Function and Subsets
The immune system works through the communication of many different types of
cells. Conventional T cells are a subtype of lymphocytes that express a TCRab and
CD8 or CD4 co-receptor and are able to respond to immunologic stimulus; they develop
in the thymus and play a critical role in adaptive immunity.45,46 There are three main
types of ab T cells: CD8+ killer T cells, CD4+ helper T cells, and regulatory T cells (also
known as suppressor T cells). Although it is understood that B cells also play an
important role in immunity, for the purposes of this thesis, the focus will primarily be on
T cells.
CD8+ T cells. Cytotoxic or killer T cells express the CD8 co-receptor on their
surface and are primarily implicated in the destruction of infected cells.47 CD8 is a cell
surface heterodimer expressed by CD8+ T cells which increases the relative TCR
affinity by binding to the invariant α3 domain on MHC class I heavy chains stabilizing
the TCR/peptide/MHC class I complex (Figure 5A).48 CD8+ T cells essentially monitor
the host and eliminate any potential threat to the body.47 Although they primarily target
pathogens, in some cases, cytotoxic T cells are also known to target tumor cells.49 The
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function of CD8+ T cells is mediated by secretion of cytokines, such as interferon g (IFNg) and/or tumor necrosis factor a (TNF-a) among others, and the expression of
granzyme or perforin molecules.50,51 Granzyme and perforin release allows CD8+ T cells
to directly drive the destruction of target cells.51 As perforin punctures the cell
membrane of cells by inducing the formation of pores, and granzyme proteases initiate
apoptosis, when a toxic mixture of these proteins is delivered to the target cell from a
cytotoxic T cell, the cell will undergo apoptosis and direct killing.51,52 Before a CD8+ T
cell’s killing mechanism can be activated, however, the cell must first recognize a
foreign antigen presented on MHC class I molecules on an APC.53

Figure 5. T Cell Subtypes. T cell subtypes and their mechanistic interactions with
APCs. A) Functionality of effector T cells in action: CD4 and MHC II interaction
compared to CD8 and MHC I. B) Regulatory T cell function demonstrating the inhibitory
effect Tregs push onto surrounding effector T cells, including cytokine activity and
suppression of CD4 T cells. Adapted from “Treg cell-based therapies: challenges and
perspectives,” by C. Raffin, 2019, Nature Reviews Immunology, Vol. 20, 158-172.
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Figure 5A demonstrates TCR and CD8+ binding to a class I MHC molecule in order to
activate the T cell and initiate an immune response. Prior to experiencing antigen and
activating for the first time, all T cells are considered “naïve”. Once they have
encountered antigen and responded to cells expressing that antigen, they can develop
into memory T cells.52
As T cells develop, they express many different phenotypic characteristics (see
Table 1). T cells differentiate from naïve, to central memory cells, to effector memory
cells. Antigen experience can be measured by many different cellular markers, but in
general, CD62LhiCCR7hiCD45RAhiCD45ROlow cells are naïve or stem cell memory cells,
and CD62LlowCCR7lowCD45RAlowCD45ROhi cells are further differentiated effector
memory cells.52
Table 1. Memory T Cell Markers and Phenotypes. This table demonstrates marker
expression of T cells as they differentiate through TN (naïve T cell), TSCM (T memory
stem cell), TCM (central memory T cell), TEM (effector memory T cell), and TTE
(terminally differentiated effector T cell) stages. Take note of CD45RO, CD45RA,
CCR7, and CD62L expression, as they are considered primary phenotypic markers for
T cell differentiation. The table includes other markers that can determine differentiation
phase that were not discussed in the text. Adapted from “T memory stem cells in health
and disease,” by L. Gattinoni, 2017, Nature Medicine, Vol. 23 (Issue 1), 18-27.
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Naïve and early memory cells show greater stemness and proliferative potential,
whereas effector memory cells display greater antigen dependence, senescence, and
cytotoxicity.54 Memory cells are maintained over time by cytokines like IL-7 and IL-15,
and their differentiation makes them more readily prepared to migrate to inflamed
tissues in the future.50,52 CD8+ T cells rely on their ability to induce cytotoxicity to directly
kill infected or cancerous cells. Although CD4+ T cells operate through mechanisms
similar to those of CD8+ T cells, their function and purpose does vary from CD8+ T cells.
CD4+ T cells. T cells that express CD4+ co-receptor also play an important role
in driving immune responses. CD4 is a cell surface monomer expressed by CD4+ T
cells which increases the relative TCR affinity by binding to the invariant β2 domain on
the MHC class II β chain stabilizing the TCR/peptide/MHC class II complex (Figure
5A).55 CD4+ T cells are responsible for secreting molecules like cytokines and
chemokines to modulate the activity of different immune cells. As shown in Figure 5A,
CD4+ T cells activate when TCR and CD4+ co-receptor bind to class II MHC molecules.
Mature CD4+ T cells can differentiate into two major populations, T helper 1 (Th1) and T
helper 2 (Th2) cells, to recruit and engage target cells.56 These two cell populations are
characterized by their cytokine interaction patterns, as the distinct cytokines they
interact with or secrete allow them to properly perform their functional duties. Th1 cells
respond to intracellular pathogens.56 They are able to secrete IFN-g, lymphotoxin a, and
IL-2.56,57 IL-12 secretion by APCs also mediates Th1 cell differentiation.56 While the
activation of the Th1 pathway is primarily geared towards attacking pathogens like
viruses and bacteria by assisting CD8+ T cells, Th2 cells more readily respond to
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extracellular pathogens, including parasites, and primarily assist B cells.57 Th2 cells also
induce allergy-driven immune responses, although Th1 cells are usually credited for
inducing autoimmune diseases.56 Th2 cells mediate their activity by IL-5, whereby their
secretion can increase antibody formation by B cells, mast cells, and eosinophils.57
Also, IL-4 interaction with CD4+ T cells promotes Th2 T cell differentiaition.57 Both Th1
and Th2 pathways employ independent pathways, but the two cell populations can also
moderate one another’s function.57 When Th2 cells secrete IL-10, they can actually
inhibit Th1 cells in an effort to reduce immune response and maintain homeostasis.56,57
Although Th1 and Th2 CD4+ T cell activation is dependent on TCR-MHC class II
binding, other costimulatory molecule binding must occur before CD4+ T cells can
become fully activated. CD4+ T cells express CD40 ligand that binds to CD40 on APCs,
and this interaction provides a critical signaling mechanism to induce specific CD4+ T
cell activation.58 Memory formation occurs in CD4+ T cells occurs similarly to CD8+ T
cells. For example, differentiation of CD4+ T cells is also characterized by the
downregulation of CD62L and CCR7.58 Th1 and Th2 CD4+ T cell populations hold an
important role in the stimulation of immune responses. Although CD8+ T cells are
primarily responsible for initiating cytotoxicity and direct killing of cells, CD4+ T cells are
invaluable to the initiation of persistent and functional immune responses. However, a
fraction of CD4+ T cells exists that is immunosuppressive, known as regulatory T cells.
Regulatory T cells. Even though the primary function of the immune system is
to stimulate immune responses, mechanisms must exist that eventually stop immune
responses. Regulatory T cells, or Tregs, are responsible for suppressing immune
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responses to prevent autoimmunity.59 Tregs are CD4+, and are characterized by their
expression of CD25 and Foxp3.60 While natural Tregs can be produced in the thymus,
inducible Tregs differentiate from peripheral CD4+ T cells, and Foxp3 expression is
critical to maintain normal function of those cells.60 Foxp3 is an essential transcription
factor for the development of Tregs.61 Foxp3 deficient mice lack Tregs, resulting in
severe and even fatal autoimmunity in mice.61 These studies highlight the critical role
that Tregs maintain within the immune system. Like other T cell populations, Tregs also
depend on cytokines to function properly. IL-2 is necessary for Tregs to maintain
expression of both Foxp3 and CD25, and helps sustain the activity of Tregs.60 Tregs
also secrete and interact with IL-7 and IL-15 to drive differentiation.61 See Figure 5B
Treg inhibition is driven by cytokine production and activation of inhibitory receptors.
Tregs bring homeostasis to the immune system by balancing out effector T cell activity.
Although CD8+, CD4+, and CD4+ Treg T cells vary vastly in their function, all T cells
begin their development in the thymus.
T Cell Development
T cells undergo a programmed selection process in the thymus during their
development that ensures they express TCR and a single CD4+ or CD8+ co-receptor
before being released into the periphery.62 During T cell development, CD4/CD8 double
negative progenitors undergo TCRab rearrangements which generate CD4/CD8 double
positive cells; those cells are then experience CD4 or CD8 downregulation, which
results in single positive cells, leading to a mixed population of naïve T cells in the
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thymus.63 A large fraction of the research that scientists have performed to understand
T cell development comes from animal models, for the sake of ethics and practicality.64
As a result, it is understood that T cells differentiate through a number of stages, and
mouse cells in particular can be followed through development by their expression of
particular cell surface markers.64 Figure 6 summarizes the development pathway in
which mouse T cells begin as CD4/CD8 double negative cells and eventually end up as
single positive T cells. Double negative cells develop in 4 stages (DN1-4). First, DN1
cells are CD44+CD25-, and DN2 cells are CD44+CD25+ and CD3 expression appears at
this stage. DN3 cells are CD44-CD25+ and undergo TCRb rearrangements, where the
new b chain complexes with CD3 and pre-Ta (a TCRa chain placeholder to maintain
stability), forming the pre-TCR, which is required for development to proceed.65,66

Figure 6. T Cell Development Pathway. Mouse T cells move through a series of
phases during development. Starting with multiple CD4/CD8 double negative (DN)
phases that are driven by CD44 and CD25 expression, developing T cells undergo
TCRb arrangements first. Once becoming CD4/CD8 double positive (DP), cells
experience TCRa rearrangement which drives selection towards single positive cells.
Adapted from “T-cell development in thymus,” by D. Shah, British Society for
Immunology, Web.
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At the final stage, DN4, cells are CD44-CD25-, at which point the cells become double
positive, TCRa rearrangements occur, and downregulation of CD4+ or CD8+ results in
single positive T cells.65,67 While human T cells cannot be followed through the stages
as closely as mouse cells, it is known that after T cells become double positive during
development, they also undergo positive and negative selection (Figure 7).

Figure 7. Positive and Negative Selection of T cells. During development, T cells
experience both positive (A) and negative (B) selection. A) Positive selection occurs
during the stage in which cells are CD4/CD8 double positive. These cells interact with
thymic cells that express self-peptides on MHC molecules, and if the double positive T
cells recognize and bind to that MHC at a low-to-moderate affinity, the T cell survives.
B) After cells go through positive selection and TCR rearrangements, they become
single positive, at which point they submit to negative selection. In this stage, single
positive cells that bind to self-peptides at a high affinity go through apoptosis, while the
rest survive.
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During the stage in which developing T cells are CD4/CD8 double positive (DP), they
undergo positive selection.68 DP cells that interact with MHC class I or II with a low to
moderate affinity in the thymic cortex are positively selected, avoid cell death, and
continue on to differentiate into single positive cells.69 On the other hand, DP cells that
demonstrate no or high affinity TCR/MHC interactions undergo apoptosis.69 Single
positive T cells that have underwent both TCR rearrangements express TCRs and
either the CD4+ or CD8+ co-receptors, through which T cells interact with other cells.70
Once they reach the single positive stage, T cells undergo negative selection in the
thymic medulla.69 T cells are selected against if they express TCRs that exhibit a highaffinity interaction with self-peptides on MHC class I or II molecules; cells that are
negatively selected undergo apoptosis.69 After differentiation and selection, developed T
cells are released from the thymus. At this point, T cells possess the necessary
structures to recognize antigens and induce immune responses. However, there are a
number of signals that T cells are required to transduce before they can fully activate
and function.
T Cell Signaling and Activation
T cells are constantly surveying and interacting with cells throughout your body.
The primary function of T cells is to distinguish healthy versus diseased cells and
destroy diseased cells when they encounter them.71 In order for T cells to function, they
must be activated through an elaborate cell signaling pathway.72 Although there are
various distinct subtypes of T cells, their activation mechanisms are similar and can be
characterized by 3 signaling events.73
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It is well known that three distinct signals are necessary for effective, sustained T
cell activation.73 Figure 8 summarizes the three signaling mechanisms that lead to T cell
activation. The first mechanism or signal 1 is the antigen-specific signal relayed through
the T cell receptor.72 The second mechanism or signal 2 is co-stimulation which occurs
through CD28 on the T cell.72 The third mechanism or signal 3 is proinflammatory
cytokine stimulation, mainly IL-12 or type I interferons.73,74

Figure 8. T Cell Signaling Mechanisms. T cell activation occurs after the successful
completion of 3 mechanistic pathways: T cell receptor/CD3 binding, costimulatory
molecule signaling, and cytokine stimulation. Adapted from “APC-derived cytokines and
T cell polarization in autoimmune inflammation,” by I. Gutcher, 2007, Journal of Clinical
Investigation, Vol. 117 (Issue 5), 1119-1127.
The first step in T cell activation is TCR engaging antigen presented by MHC class I or
class I on the target cell.75,76 TCR function is dependent on the proper assembly of the T
cell receptor complex which includes the TCR αβ heterodimer and the six chain CD3
complex which consists of a CD3d/CD3e heterodimer, a CD3g/CD3e heterodimer, and a
CD3z homodimer.77-79 Early T cell activation is initiated when TCR-CD3 complexes
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recognize peptides that are presented MHC molecules on APCs.80 The sensitivity of
TCRs and their affinity heavily affect T cell activation with higher affinity reactions
typically generating stronger activation signals.81 TCR triggering refers to the events that
occur after the initial TCR-peptide interaction, which encompasses the phosphorylation
of CD3z and the resulting initiation of a signaling cascade that amplifies the signal to
continue the activation pathway.80 As previously discussed in the T cell development
section, TCR affinity for pMHC is generally low to moderate which prevents strong
binding to self-antigens which can lead to autoimmunity. Therefore, for most T cells, the
CD4 or CD8 coreceptor is required for T cell activation and function. In addition, the
tyrosine kinase lck is bound to the cytoplasmic region of CD4 and CD8.82,83 When CD4
or CD8 bind to the MHC, it brings lck into close proximity to the CD3 complex,
facilitating phosphorylation of the immunoreceptor tyrosine-based activation motifs
(ITAM’s) on CD3ζ chain, leading to more efficient T cell activation.84 Although T cells
can activate and function after signal one alone, T cell usually become anergic after
receiving signal one alone.72 Therefore, signal two is considered necessary for initiating
long term persistence of immune activation.72
Signal two of T cell activation is binding of costimulatory molecules. This
mechanism is typically lead by CD28 when it binds to its ligands CD80 and CD86.85 The
costimulatory signal is transmitted through the ligand-bound receptor and the resulting
downstream signaling of CD28 upregulates a number of T cell mechanisms, including T
cell differentiation, cell cycle progression, and cytokine production.85 Although CD28
binds to CD80/86, an inhibitory receptor, CTLA-4, competes with CD28 for binding to
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the same ligands.86,87 CTLA-4 binds to both CD80 and CD86 at a higher affinity than
CD28, but their differences in temporal expression greatly minimizes binding
competition between CD28 and CTLA-4.87,88 CD28 is expressed on resting T cells, so
the receptor is prepared to bind to its ligands when the T cell becomes activated.86,89 T
cells maintain CD28 expression while the cell is activated; however, CTLA-4 expression
is prompted after T cell activation, particularly after CD28 binding and costimulation.86,89 The inhibitory signals relayed through CTLA-4 function to stop T cell
activation once the immune response is completed to prevent excessive inflammation or
exhaustion.86 This balance of immune activation and suppression is also critical to
inhibit autoimmunity.90 Studies have shown that CTLA-4 blockade in mice can induce
spontaneous autoimmunity, highlighting the sensitivity between the balance of immune
activation and suppression and the important role it plays in maintaining normal immune
function.90 Despite the ability of T cells to function normally and maintain activation after
receiving the first two signals, it is known that a third signal, cytokine stimulation, drives
sustained T cell activation and initiates the strongest effector functions.73
Signal three is mediated primarily by inflammatory cytokines IL-12 and Type I
IFN which play major roles in T cell responses by supporting memory formation,
enhancing anti-tumor immunity, and inhibiting cell death and tolerance.91 Although T
cell activation is necessary for T cells to function, persistent signaling can lead to T cell
abnormalities. After T cells become activated and an immune response has been
completed, T cells should undergo senescence and apoptosis or differentiate into
memory cells. However, cells that escape these pathways, and, for example, sustain
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prolonged activation, are dysfunctional.92 Excessive antigen exposure and activation
can induce T cell exhaustion which can cause loss of effector function and expression
of inhibitory receptors like PD-1 and LAG3.93 Binding of inhibitory receptors such as PD1 or CTLA-4 can directly suppress the immune response, meaning that when T cells
become exhausted, their inhibitory mechanisms prohibit them from driving an effective
immune response against the pathogen.94 In all, the immune system is a very powerful
yet sensitive mechanism, and it relies on a perfect homeostasis between all of its
individual parts in order to function properly. Chronic disease and immune dysfunction
often present simultaneously, and it is well known that in patients with diseases like
cancer, the immune system is heavily compromised.
Cancer Immunotherapy
The immune system has become a critical component of cancer care. New
understandings in cancer cell behavior has elucidated that immune system disfunction
and chronic inflammation are symptoms of tumor formation that can actually drive
disease progression.95 Because of this, modulating the host immune system has been
established as a potentially effective way to treat cancer in humans. Through
advancements in cancer biology, cancer immunology, otherwise known as
immunotherapy, has blossomed.95 Cancer immunotherapy is now a rapidly evolving
field. With the constant introduction of new tumor targets and treatment methods, the
clinical responses of immunotherapy have increased the enthusiasm and confidence in
using it to fight cancer.96 Although there are plenty of hurdles to overcome, using the
immune system to defeat cancer stands to be an extremely promising road. Because
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cancer immunotherapy is a major topic in the discipline of immunology, especially after
the Nobel Prize in Physiology or Medicine was awarded to Doctors James Allison and
Tasuku Honjo in 2018 for their research in immune checkpoint blockade, it is often
misunderstood to be a relatively new field of research.97 However, cancer
immunotherapy has a long and rich history that has lead the field to where it stands
today.
History of Cancer Immunotherapy
Early contributors to the field of tumor immunology were scientists like Paul
Ehrlich, who not only elucidated mechanisms and functions of the immune system in
general but sought to apply that knowledge to fight cancer. Ehrlich’s early papers
described observations in which tumors can be suppressed by the immune system, and
his immunology work earned him the Nobel Prize in Physiology or Medicine in 1908.98,99
Interest in immunotherapies waned, but renewed in the mid-1900’s when novel
applications were introduced.99 The first successful bone marrow transplant was
performed in 1957 with a healthy donor providing the transplant to their sibling with
acute leukemia.100 This experiment included allogenic patients as well, but only the
syngeneic transplant worked, which eventually lead to the concept of matching donors
and recipients.100 Cancer vaccines were also being developed and applied
therapeutically in the late 1950’s.99 Old et al described successful experiments where
mice with bladder cancer were administered the tuberculosis vaccine, Bacille CalmetteGuérin (BCG), in an effort to activate immune responses against the tumor.101 The next
major discovery in cancer immunotherapies were the production and application of
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monoclonal antibodies.99 Köhler and Milstein were the first to generate monoclonal
antibodies in a laboratory setting in 1975.102 It wasn’t until 1982 that James P. Allison
applied monoclonal antibodies experimentally to identify and target tumor-specific
antigens in mice, which was a significant discovery at the time.103 IL-2 was cloned in
1983, leading to an explosion of new cancer immunotherapies and applications.104
Shortly after IL-2 was cloned, Steve A. Rosenberg used lymphocytes incubated in IL-2
to produce lymphokine-activated killer (LAK) cells and demonstrated their effectiveness
in targeting cancer in humans.105 Rosenberg expanded his research in the following
years, and eventually introduced a new method of adoptive cell transfer using tumorinfiltrating lymphocytes (TIL) cultured in IL-2.106 In 1988, Rosenberg produced incredible
results using TILs cultured in IL-2, when he reported a 60% regression rate in patients
with metastatic melanoma that received TIL who hadn’t been treated with IL-2 therapy
previously.107 These discoveries lead the way for the introduction of adoptive cell
transfer of genetically engineered T cells.108 It was also during this time that the first
immune checkpoint, CTLA-4, was discovered.99,109 Although its function was not initially
known, James P. Allison elucidated the mechanisms of CD28 and CTLA-4 coexpression in 1995 and described CTLA-4’s immune suppressive signaling.110 This lead
to the immediate development of CTLA-4 blockers and their application in cancer
immunotherapies.111 These scientists and their research were critical in propelling the
field of cancer immunotherapy to the place it is today. These experiments directly lead
to the eventual FDA approval of many different cancer immunotherapies, including: IL-2
therapy, the monoclonal antibody rituximab, the CTLA-4 inhibitor ipilimumab, the PD-1
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inhibitor nivolumab, the oncolytic virus T-VEC, and CAR T cells. Cancer immunotherapy
has come a long way since its inception, and novel targets and methods have allowed
modern therapies to be more effective than ever before.
A subset of modern cancer immunology is focused on engineering immune cells
to make them better equipped to recognize and respond to diseases like cancer,
wherein otherwise they are non-functional.95 As a result, genetic engineering of immune
cells has expanded greatly over time, and as of today it stands as a successful
treatment option for cancer patients who have failed standard-of-care therapies.
Although immunotherapy comes in many different forms, a portion of current research is
focused on making established treatment methods more effective. One of those
treatments, which is the focus of this thesis, is adoptive T cell therapy (ACT).
Adoptive Cell Transfer of T Cells
Adoptive cell therapy, in general, refers to a type of therapy in which cells are
transferred into a patient. In immunotherapy, the transferred cells are typically T cells
best illustrated by tumor infiltrating lymphocytes (TILs), or engineered T cells such as
TCR modified T cells or CAR T cells.112 These therapies have shown success in
increasing the survival of cancer patients with both solid tumors and hematologic
malignancies.2,113 All three therapy models show clinical potential and offer promising
approaches to elicit anti-tumor responses in humans.114-116
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Tumor infiltrating lymphocytes (TILs). T cells, like other immune cells, are
chemotactic and migrate to sites where inflammation and antigen are present. Tumor
cells are generally antigenic but often elicit poor immune responses for many reasons.
Not all immune cells can migrate into solid tumors.117 However, in tumors like
melanomas, where a large number of T cells are found, it is reasonable to hypothesize
that some or many of those infiltrating T cells are tumor reactive.117 These tumor
infiltrating lymphocytes or TIL can be isolated from resected tumors from a patient,
expanded ex vivo, and then given back to a patient (Figure 9).4

Figure 9. Methods of Adoptive T Cell Therapies. Methods of adoptive T cell transfer
follow similar methods of production. TIL therapy begins when TIL are isolated from
tumor lesions ex vivo. The isolated cells are tested for tumor-reactivity, and reactive
cells are selected and expanded ex vivo. After expansion, the tumor reactive TIL are
infused back into the patient. On the other hand, TCR and CAR T cell therapies are
given by first isolating T lymphocytes from patient blood. Those cells are genetically
engineered ex vivo, by transduction or other methods of engineering, and the resulting
modified cells are expanded. The newly modified cells are then infused back into the
patient.
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It’s been shown that some melanoma patients respond well to adoptive cell transfer of
TILs.118,119 Because it stands as a highly personalized therapy, this therapy has worked
as a treatment to multiple different types of cancer.120 For example, TILs are known to
be present in ovarian cancer (OC), and is a positive factor when determining
prognosis.121 TIL therapy has also been effective in treating patients with HPVassociated cervical cancer, triple negative breast cancer, and renal cell carcinomas.122124

While TIL therapy focuses on expanding an endogenous population of cells, it is not

possible to isolate TILs in all patient cases, and genetically modifying cells offers a
solution to produce tumor-reactive T cells from a patient’s non-reactive T cells.
T cell receptor (TCR) modified T cells. During development, T cells that
recognize self-antigens at a high affinity are negatively selected, preventing them from
entering the peripheral T cell repertoire (Figure 7). As a result, endogenous T cells
normally do not effectively recognize self-antigens. Although this process is meant to
eliminate autoimmunity, it renders the large majority of endogenous T cells ineffective
against tumors because tumors express self-antigens.125 It is known that the immune
system can recognize tumor cells, and although those cells are usually eliminated
during development, those that escape are functionally limited.126 As previously
discussed, T cell receptors (TCRs) are the most critical component of signal one, which
is antigen recognition by a T cell, and TCR affinity can influence subsequent T cell
activation.72 Therefore, it is possible to identify or design TCRs that recognize specific,
overexpressed tumor antigens.49 From there, T cells can be isolated from patients and
genetically modified to express those TCRs, and the new TCR gene modified T cells
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can be administered back into the patient (Figure 9).127 Figure 10A shows an example
of a retroviral vector containing a TCR that transfer HLA-A2 restricted, hTERT reactivity
to T cells fused by a 2A self-cleavage peptide to an mCherry tag that can be used to
measure transduction efficiency of the TCR modified T cells in vitro. Figure 10B
demonstrates mCherry expression by hTERT TCR transduced T cells. In the histogram
on the left, untransduced T cells do not express mCherry, as 0.42% of those cells were
mCherry positive (Figure 10B). On the other hand, 55.6% of T cells transduced with the
mCherry construct expressed mCherry at relatively high frequencies (Figure 10B). Foley
et al previously reported that marker gene expression has a linear relationship to
properly assembled TCR expression, meaning a high number of mCherry+ cells and
high level of mCherry expression by the hTERT TCR transduced T cells in the culture
suggests the production of an hTERT reactive T cell culture.128 The antigen reactivity of
this hTERT TCR transduced T cell culture was confirmed using a cytokine release
assay as shown in Figure 10C. hTERT transduced T cells were co-cultured with a
number of control or experimental cell lines overnight and IFN-g secretion in the cultures
were measured on day two via an enzyme-linked immunosorbent assay (ELISA) kit
(See Figure 10C). In the presence of target cells expressing hTERT peptide (T2 cells
pulsed with hTERT peptide and UOK131 tumor cells), hTERT transduced T cells
showed increased production of IFN-g compared to the negative controls, in which the T
cells were cultured alone (Media) or with tumor cells that do not express hTERT (62428Mel), suggesting that the transduced T cells maintained functionality and hTERT
reactivity (See Figure 10C).
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Figure 10. Example of Modified TCR T Cells Used in Immunotherapy. DNA
sequence, flow cytometry results, and ELISA results for mouse T cells transduced with
the construct shown. A) T cell receptor DNA construct containing the hTERT TCRa and
TCRb sequences, with an mCherry fluorescent marker on the terminal end. B) Flow
cytometry data analyzing mCherry expression on untransduced (left) and transduced
(right) mouse T cells. Transduction efficiency was measured via mCherry expression,
and approximately 55.6% of cells that underwent the transduction protocol successfully
took up the construct and demonstrated modified TCR expression. C) hTERT
transduced T cells from (B) were co-cultured overnight in media, with T2 cells pulsed
with hTERT peptide, with hTERT+ UOK131 tumor cells, or with hTERT- 624-28Mel
tumor cells, and IFN-g secretion was measured using an ELISA MAX kit (BioLegend).
Average measure of IFN-g in pg/mL is given above each sample bar. Top standard was
set to 1000 pg/mL, and samples above top standard are marked with an *asterisk.
These results demonstrate the power of gene modifying T cells with TCR genes to alter
their antigen recognition.
Although adoptive transfer of TCR gene modified T cell is being used to treat a
number of different cancers, a large fraction of TCR T cell therapy research is focused
on melanoma, and is followed by leukemias and lymphomas.129 Many effective
antigenic targets have been identified for use in genetically modified T cell therapy
against melanoma, including Tyrosinase, MART-1, gp100, and NY-ESO-1.130-134
Although this method of therapy has been well established and proven functional, a
strong limitation to it is that these genetically engineered T cells still require to be
activated via traditional pathways, which is not always easy to accomplish in the tumor
microenvironment.
Another class of T cells with genetically modified T cell receptors are chimeric
antigen receptor (CAR) T cells. CAR T cells can efficiently target tumors and activate
independently of costimulatory signaling or cytokine stimulation, making the tumor
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recognition system much more sensitive than TCR transduced T cells, which need to
activate via the normal T cell signaling mechanisms as described previously.
Chimeric antigen receptor (CAR) T cells. Chimeric antigen receptors are
artificially produced receptors that are engineered allow T cells to target specific tumor
antigens. Similar to TCR T cell therapy, CAR T cells are usually generated by isolating
patient normal T cells and transducing them with viral vectors encoding the CAR.135
After the CAR T cells are generate, they are expanded and infused back into the
patient.135 Therefore, depending upon the CAR available, autologous T cells can be
produced that target any malignancy.
Although the therapy regimens are very similar, there are two fundamental
differences between TCRs and CARs used for engineering T cells (Figure 10, Figure
11). First, CAR targets are cell surface molecules where TCR targets are peptide
fragments derived from both cell surface and intracellular molecules bound to MHC
molecules.135 Second, CAR receptors are considered chimeric because they possess
the molecules necessary to initiate antigen binding as well as T cell activation.135 The
basic general structure of a CAR is shown in Figure 11. A CAR consists of a single
chain variable fragment (scFv) that contains the antigen binding molecules of the heavy
and light chain regions of an immunoglobulin molecule fused to a CD3z signaling
domain.136 The scFv region is responsible for antigen recognition and binding while the
CD3z signaling domain is responsible for initiating and driving T cell activation.135 This
chimeric scFv/CD3z protein, known as a first-generation CAR, contains all the
necessary components required for T cell activation in a single construct thus directly
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activating the T cell upon binding antigen. However, T cells expressing a first-generation
CAR lack signal 2 or costimulation meaning their long-term persistence and memory
formation in vivo is poor; therefore, modifications have been made to the first-generation
CAR constructs to costimulatory molecule cassettes such as CD28 or 4-1BB.135

Figure 11. Chimeric Antigen Receptor (CAR) structure compared to standard T
cell receptor. Traditional T cell receptors are made up of a TCR αβ heterodimer and a
multi-chain CD3 complex which contains a CD3d/CD3e heterodimer, a CD3g/CD3e
heterodimer, and a CD3z chain. All CARs contain an extracellular domain that is made
up of a variable light chain (VL), variable heavy chain (VH), and single-chain variable
fragment (scFv). CARs differ in their intracellular domains. First generation CARs
contain a CD3z alone. Second generation CARS contain a costimulatory molecule
(CD28 or 4-1BB) and CD3z. Third generation CARs contain two costimulatory
molecules (CD28 and 4-1BB) linked to CD3z. Adapted from “CAR T cell immunotherapy
for human cancer,” by C. June, 2018, Science, Vol. 359 (Issue 6382), 1361-1365.
These second generation CARs are the mostly widely used CAR design constructs and
the two FDA approved CAR T products use CD19 CAR’s containing a CD28 (Yescarta Kite/Gilead) or 4-1BB (Kymriah - Novartis) costimulatory cassette.136 Further
improvements were made on the second generation CAR design by inserting two
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costimulatory cassettes instead of just one (CD28 and 4-1BB).136 The third generation
CAR design does not have added benefits over the second generation CAR constructs
and have not been utilized in most clinical trials.
CAR T cell therapy has proven to be a very effective treatment for cancer, as
there are two CAR T cell products that are now FDA-approved, axicabtagene (Yescarta
- Kite/Gilead) for adult diffuse large B cell lymphoma subtypes, and tisagenlecleucel
(Kymriah - Novartis) for pediatric acute lymphoblastic leukemia.137 Although CAR T cell
therapy has been very successful in treating hematologic malignancies, their efficiency
in treating solid tumors has not been well-elucidated.138-140 Significant effort has been
devoted to developing CAR T cell therapies for treating solid tumors like neuroblastoma,
pancreatic cancer, and non-small cell lung cancer.141-143 Despite the effort, CAR T cells
currently remain only effective in hematologic malignancies.139,144 There are a number
of unique challenges that solid tumors present compared to hematological
malignancies. For example, CAR T cells struggle with trafficking to and infiltrating
tumors as a result of the strongly immunosuppressive tumor microenvironment.145,146
Lack of tumor-specific antigens to target is another large obstacle that stands in the way
of using CAR T cells to effectively produce clinical results.139,145
In summary, adoptive cell therapy primarily focuses on increasing activity of T
cells by directly engineering them. However, other immunotherapies focus on
modulating signaling mechanisms that influence how these cells behave and function to
increase their activity, such as cytokine therapies.
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Cytokine Therapy
Despite the presence of T cells in tumor lesions, these T cells fail to induce tumor
regression in cancer patients. Similarly, the infusion of large quantities of ex vivo
activated and expanded T cells into cancer patients often has no impact on the
progression of their disease. Therefore, it is clear that factors other than the presence of
tumor reactive T cells influence T cell function in vivo. One group of molecules that can
have a profound impact on T cell biology is cytokines.75 Cytokines are a large group of
soluble proteins that mediate cell communication and signaling.147 Because cytokines
are very diverse, their influence on the immune system varies depending on the specific
cytokine being studied, as some cytokines are pro-inflammatory, and others are antiinflammatory.147 While several cytokines have been evaluated as a monotherapy to
treat different types of cancer, the majority of the studies have focused on interferon-a
(INF-a) and interleukin-2 (IL-2).
INF-a has been approved by the FDA for use in humans, mainly as an anti-viral
therapy. It normally functions to stimulate inflammatory mechanisms during viral
infection by detecting abnormalities within double stranded DNA. INF-a also blocks
translation within infected cells to inhibit replication of the virus.147 However, the effects
of INF-a can also promote immunity against tumor cells.147 INF-a is able to stimulate
anti-proliferative signaling to induce anti-tumor activity, and it is used to treat
hematological malignancies and solid tumors like leukemia, melanoma, Kaposi’s
sarcoma, and lymphoma.148-151
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IL-2 therapy has also been FDA approved for use in patients. There are three IL2 receptor chains expressed on immune cells in which IL-2 interacts with: IL-2Ra, IL2Rb, and common g chain. The low affinity IL-2 receptor contains an IL-2Ra chain
alone, the intermediate affinity receptor is composed of the IL-2Rb and common g
chains together, and the high affinity receptor consists all three IL-2Ra, IL-2Rb, and
common g chains.152 When IL-2 engages with intermediate or high affinity receptor
complexes, signaling to initiate transcription via the JAK/STAT, PI3K, and MAPK
pathways begins, promoting activation, differentiation, and cell proliferation.152 When it
comes to treating cancer, IL-2 monotherapy has demonstrated effectiveness in
activating T cells and natural killer cells within the tumor microenvironment.152 This form
of immunotherapy has been approved for treating metastatic renal cell carcinoma as
well as metastatic melanoma, and approximately 15% of patients who receive this
treatment demonstrate a clinical response.147,153-155 Although INF-a and IL-2 are
currently the only cytokine monotherapies that are FDA-approved, there are a number
of potentially effective treatments being studied now.
Both IL-2 and INF-a are pro-inflammatory cytokines, as are IL-12, IL-15, and
granulocyte-macrophage colony-stimulating factor (GM-CSF). Antigen-presenting cells
like DCs, B cells, and macrophages produce IL-12, and the released IL-12 interacts with
IL-12 receptors on T cells and natural killer cells.156 Activation of the IL-12 receptor
eventually leads to IFN-g secretion which generates a positive feedback loop to activate
the cell and others around it.157 By potentiating immune responses, IL-12 monotherapy
has become a promising cancer treatment as research suggests it can induce anti-
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tumor immunity.158 IL-15 activation occurs via a similar pathway. When IL-15Ra in
complex with IL-15 is expressed on producer cells, the receptor can interact with IL-2/IL15Rb and a common g chain on the target cell, resulting in proliferation, increased
cytotoxicity, and release of cytokines by producer cells to attack and destroy target
cells.147,159-161 IL-2 is known to stimulate Treg populations, whereas IL-15 does not,
which suggests that the anti-tumor effects induced by IL-15 are potentially stronger than
that of IL-2.147,162,163 GM-CSF is a white blood cell growth factor. By stimulating
granulocytes and monocytes, GM-CSF activates a signaling cascade that allows those
cells to activate and proliferate rapidly, which is a potentially effective method to
stimulate anti-tumor responses.147,164 Although many cytokine therapies operate by
stimulating inflammation and immune activation, other therapies function by inhibiting
the immune suppression that cancer cells drive.
Immune Checkpoint Inhibitors
Tumor cells possess abilities to suppress the anti-tumor immune response
through a variety of mechanisms, and they are derived from host tissues and present
self-antigens. Along with activating mechanisms that attract Treg cells and secreting
immunosuppressive cytokines, tumors also activate immune checkpoints.165 Antigen
presenting cells express checkpoint ligands and T cells express checkpoint receptors
that regulate T cell function.94 Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) is
an immune checkpoint that is thought to inhibit immune cell activation by
downregulating T cell proliferation.166 Downregulation of immune responses by CTLA-4
occurs when CTLA-4 receptors on T cells bind to CD80/CD86 ligands expressed on
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tumor cells.167 Although CTLA-4 shares the CD80/CD86 ligands with CD28, CTLA-4
binds to both ligands with a higher affinity than CD28; this suggests that CTLA-4 and
CD28 compete for ligand binding, and CTLA-4 may be an antagonist of T cell
costimulation by CD28.168,169 Therefore, CTLA-4 blockade allows T cell activation
directly by allowing CD28 costimulation, and clinical results have demonstrated antitumor effects in patients.89,170 PD-1 is another immune checkpoint receptor expressed
on T cells. When T cells are exhausted, they typically demonstrate higher expression of
PD-1. When PD-1 interacts with programmed death ligand 1 or 2 (PD-L1 or PD-L2) on
tumor cells, IFN-g secretion, IL-2 production, and T cell proliferation are all inhibited.166
However, PD-1 blockade seems to reverse exhaustion.166,167 Blocking PD-1 restores
immune activation and function by inhibiting PD-1 binding to either PD-L1 or PD-L2, and
has also shown clinical success as a cancer therapeutic.166,171 To summarize, binding of
inhibitory receptors CTLA-4 and PD-1 to their ligands deactivates T cells and prohibits
further signaling and T cell function, resulting in downregulation of immune
responses.167 Therefore, it is possible to block these receptor/ligand interactions using
antibodies, consequently inhibiting the immune suppressive activity within the tumor
microenvironment mediated by PD-1 and CTLA-4 binding.111 Figure 12 demonstrates
the function of immune checkpoint blockers.
Anti-PD-1 and anti-CTLA-4 antibodies have both been used to treat different
types of cancer. Ipilimumab, an anti-CTLA-4 antibody has been FDA approved for use
to treat melanoma, and Nivolumab, an anti-PD-1 antibody, is approved for use in
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melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, and
numerous other types of cancer.165,172

Figure 12. Immune Checkpoint Blockade. CTLA-4 and PD-1 are both inhibitory
receptors expressed on immune cells, including T cells. They bind to their respective
ligands on tumor cells to induce immunosuppression. Tumor cells exhibit enhanced
expression of these inhibitory ligands to induce suppression of immune cells within the
tumor microenvironment. Immune checkpoint blockers typically come in the form of
monoclonal antibodies, and work by binding to the inhibitory receptors on immune cells
to block immune inhibitory responses, thereby allowing immune cell activation.
Combination treatment using Ipilimumab and Nivolumab has also been approved for
melanomas and renal cell carcinomas, as combining the two blockade therapies can
lead to increased expansion of tumor-infiltrating lymphocytes compared to single
blockade therapy.165,173 In clinical trials, objective response rates of patients receiving
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combination therapy of PD-1 and CTLA-4 blockers were 61.1%, whereas patients
receiving a single CTLA-4 blocker demonstrated a significantly lower response rate of
10.8%.174 Although evidence demonstrating clinical effectiveness as a result of primary
treatment alone have been collected, secondary anti-tumor effects can be observed
after administration of these treatments. For example, cross priming of the immune
system has been strongly linked to long-term onset of anti-tumor immunity after
administration of immunotherapy.
Cross Priming
One concern with many immunotherapy and gene modification strategies is that
these therapies target single antigens, therefore, cross priming the immune system to
be better equipped to respond to multiple antigens stands to be an extremely effective
method to treat diseases. Although the primary purpose of cancer treatment is tumor
elimination, the secondary effects of administering immunotherapies have a potentially
significant impact as well: cross priming.175 Cross presentation occurs when exogenous
antigens are presented to CD8 T cells via MHC class I molecules, and this process can
lead to immunity against the antigens released by the targeted cells, resulting in priming
of the immune system against those particular antigens.43,176,177 When tissue
destruction occurs, cellular debris containing tumor-specific peptide antigens spill into
the extracellular matrix.175 From there, those antigens can be taken up, processed, and
subsequently presented by nearby APCs to activate CD8+ cytotoxic T cells and illicit a
strong immune response.178 This method of antigen presentation produces tumorspecific CD8+ T cells for the target antigen as well as other antigens released from the
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destroyed tumor cells.179 For example, clinical data shows that patients with metastatic
melanoma treated with NY-ESO-1-specific CD4+ T cells eventually develop T cells that
are reactive to tumor cells expressing not only NY-ESO-1, but other melanoma-specific
tumor antigens like MART-1 and MAGE-3.179,180 This data paired with other research
strongly suggests that targeting a single antigen can drive systemic immunity against
other antigens to significantly improve the outcome of cancer treatments.181,182
Although immunotherapies are well developed and, in some cases, FDAapproved, there are restrictions to their efficacy. Tumors employ mechanisms to inhibit
the function of endogenous primed tumor-specific T cells and even exogenous modified
T cells.
Limitations of Current Immune Therapies
Despite the development of many different immunotherapies, scientists still
struggle to see consistent and sustained clinical responses from patients receiving
these treatments. Whereas current cancer therapies work remarkably for some patients,
they’re not successful for all patients. The first step to overcoming these challenges is to
address what biological mechanisms are inhibiting the onset of complete responses in
patients. The most prominent issue that patients face is that their anti-tumor responses
are not established or sustained long term.
Non-Sustained Responses
Resistance. As previously discussed, to improve the efficacy of cancer
immunotherapies, scientists need to understand the factors that limit treatment from
reaching their maximum potential. Tumors have evolved to develop resistance
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mechanisms to immunotherapy as well as other forms of cancer therapy. There are
different types of resistance when it comes to immunotherapy: primary, adaptive, and
acquired. Primary resistance occurs when the patient does not respond to therapy
whatsoever.183 Lack of T cell recognition of tumor cells after immune checkpoint
blockade or ACT is an example of primary resistance, and is likely caused by the
absence of tumor antigen expression.183,184 Adaptive resistance is a mechanism in
which the immune system recognizes cancer cells, but the tumor employs defense
mechanisms to adapt to the attack and protect itself.183 Mechanisms that can induce
adaptive resistance include alterations to antigen processing and presentation
mechanisms that lead to reduced antigen expression or the activation of immune
checkpoints that inhibit immune cell activation in the tumor microenvironment, despite T
cell recognition of tumor cells.183 Finally, acquired resistance is a term used to describe
a scenario where the cancer initially responded to treatment, but the effect eventually
faded and the cancer relapsed.183 A major challenge in immunotherapy is to induce
persistent anti-tumor immunity, and acquired resistance is an obstacle to driving longterm responses. Although secondary tumors can be new and are not always recurrent
primary lesions, acquired resistance usually occurs after complete loss of antigen
expression, T cell dysfunction, and altered cytokine signaling.183,185 Loss of IFN-g
function, increased activity of immune checkpoints, and even reduced antigen
expression can all account for mechanistic resistance to cancer therapies.186 However,
tumor heterogeneity is another cause for minimal response or complete nonresponsiveness in patients.
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Tumor heterogeneity. The genomes of cancer cells are incredibly unstable,
leading to a number of genetic inconsistencies and differences within the cells of a
single tumor. Accelerated mutation rates among cancer cells drive dysfunction of DNA
repair mechanisms, and the outcome of which is tumor genetic heterogeneity.187,188 In
other words, although the cells within a tumor typically originate from a single cell, high
mutation rates result in tumors containing cells of many different phenotypes. When
tumors demonstrate varied molecular and cellular characteristics, it is difficult to
eliminate all of those cells with a single therapy, especially using treatments that target
single antigens.189 Whereas certain immunotherapies can induce anti-tumor immunity
regardless of tumor heterogeneity, most patients remain unresponsive to treatment or
develop resistance to treatment over time. For example, prostate tumors are known to
be multi-focal and are highly heterogenous.190 The poor prognosis of a prostate tumor
diagnosis is due in part to the fact that current therapies are not able to efficiently target
and generate a response against extremely heterogenous tumors, especially since
those tumors tend to be aggressively metastatic.190 Despite the development of novel
and combination therapies, tumor heterogeneity is maintained as a major obstacle to
inducing persistent anti-tumor responses. Furthermore, another issue that can result
from general tumor heterogeneity is antigen escape.
Antigen escape. The focus of many methods of immune therapy is to enhance
the ability of T cells to recognize and target antigens presented on tumor cells, such as
in the case of CAR T cells or TCR T cells. However, it is well known that tumor cells
have the ability to evade destruction by manipulating antigen presentation. For example,

46
when tumors of patients who are treated with CD19 CAR T cells demonstrate antigen
escape, they can experience outgrowth of CD19 negative tumor cells.191 These patients
who initially responded to therapy relapse with a disease that has an extremely similar
phenotype, except they no longer possess CD19 positive cells. This is especially
problematic considering that initial responses are often incredibly promising, as
response rates typically range from 70-90% in pediatric and adult B-cell acute
lymphoblastic leukemia (B-ALL) patients that receive CD19 CAR T cell therapy.192
Mechanisms that cause CD19 splicing variants and lack of CD19 transmembrane
domain formation, which lead to complete loss or reduced surface expression of CD19,
explain why some of these tumor cells are able to escape detection, survive, recover,
and result in relapse of disease.192 Another form of antigen escape stems from impaired
antigen presentation on tumor cells. Beta-2 microglobulin (b2M) is essential to the HLA
class I complex, as it associates with a1, a2, and a3 chains to hold the complex
together. Data strongly suggests that mutations in b2M lead to dysfunctional HLA
complexes, in which antigen presentation is impaired or inhibited completely as the
MHC molecule is not stable.193 Antigen loss can also occur due to alterations within the
antigen processing mechanisms, such as mutations directly within MHC genes, defects
in peptide development stemming from mutations in proteasomal components like
LMP2 or LMP7, or faulty peptide transport/loading systems caused by dysfunctional
TAP1 or TAP2.194 Methods to avoid antigen escape of tumor cells include targeting two
different antigens in CARs to ensure that no tumor cells are left over after therapy, and
using combination treatments to enhance initial anti-tumor effects.191,192 The presence
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of immune cells within the tumor microenvironment also stands to be an important factor
for the onset of anti-tumor immunity.
Cold tumors. The level of immune cell infiltration within a tumor dictates whether
it is “hot” or “cold.” Hot tumors demonstrate a high level of T cell inflammation and
immune infiltration, whereas cold tumors are non-inflamed and at most exhibit low levels
of immune cell infiltration. It’s been observed that cold tumors are significantly more
difficult to treat due to the lack of adaptive immune responses present prior to and
during treatment.195,196 The absence of T cell signaling and activation within the tumor
microenvironment reduces the chances of engrafted cell survival for cell therapies, and
impaired flow of cells into the tumor can render other types of immunotherapy
ineffective.195 However, methods to turn cold tumors hot by re-activating the immune
system within the tumor microenvironment are being explored. Checkpoint blockade
inhibitors are a promising solution to dealing with cold tumors, as anti-CTLA-4 and antiPD-1 therapy are used to inhibit their activity, which promotes immune suppression, as
discussed previously.197 Infusion with NK cells, genetically modified T cells, and even
nanoparticles is also able to produce a tumor microenvironment that is better suited for
inducing anti-tumor responses.195,198 Although generating a favorable environment to
manage an effective response in the first place stands to be a major hurdle in cancer
immunotherapy, other challenges include side effects as a result of therapy. Some of
these side effects can be dangerous and even fatal, especially in the case of high
toxicity from treatment.
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Toxicity from Therapy
Non-responsiveness to immunotherapy is a large obstacle that limits the
effectiveness of therapy, however, hyperresponsiveness as a result of treatment is also
a major risk. Because cancer therapies seek to drive self-antigen recognition, it is
possible that therapies induce non-tumor specific responses that attack normal cells
and tissues. These risks are present in essentially all types of immunotherapy, including
cytokine therapy, adoptive cell therapy, and checkpoint inhibitor therapy. Although IL-2
and IFN-a are FDA-approved for cancer treatment, cytokine therapies are strongly
linked to adverse events and toxicity.199 High-dose IL-2 therapy requires inpatient
monitoring because the probability of toxicity is so high, and even though IL-2 toxicity
inhibitors have been discovered, they haven’t been able to mitigate IL-2 toxicity without
diminishing anti-tumor effects of therapy.199 Furthermore, IL-2 mutants have been
developed to enhance anti-tumor effects while simultaneously minimizing the frequency
of toxicities and adverse events.200 These mutants have shown anti-tumor activity
clinically, but despite these efforts, serious adverse events are still common after
cytokine therapy.201 Cytokine release syndrome (CRS) also causes toxicity and occurs
when a large population of white blood cells activate and release cytokines, which
generates a strong positive feedback loop to induce further immune cell activation and
dangerous levels of inflammation. CRS can result in high fever, tachycardia,
hypotension, hypoxia, and other potentially life-threatening organ dysfunction.137 Both
high-dose IL-2 and adoptive cell therapies can induce CRS, it is most common after
administration of CAR T cells.202,203 Although clinical data demonstrates that FDA-
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approved CAR T cell therapy tisagenlecleucel generates complete responses in 40% of
patients, 22% of patients experience high-grade CRS.204 TCR modified T cell and CAR
T cell therapies can also induce autoimmunity; since the purpose of their genetic
modification is to give them the ability to recognize self-antigens, some of which may
not be tumor-specific, these therapies can cause immune cells to attack normal cells
and tissues.199 Immune related adverse events can also occur after checkpoint inhibitor
therapy. Using monoclonal antibodies to block immune inhibitors like PD-1 and CTLA-4
is a common method of cancer therapy, and the associated risks of therapy include
antibody-dependent cell-mediated cytotoxicity.205 Although these therapies show
promising clinical outcomes, there are a number of inherent risks that come with
manipulating immune system functions. These toxicities can be fatal, and despite the
enthusiasm that exists for these immunotherapies, there is a call for increased
awareness of the long-term complications that can arise from them.206 As a result,
methods to enhance efficacy of therapy and minimize adverse effects without
diminishing anti-tumor responses have been sought after.
Methods to Enhance Clinical Efficacy of Immunotherapy
Immunotherapies have proven to be beneficial to cancer patients despite tumor
cells’ ability to evade immune detection. New approaches to enhance and improve
therapeutic response have been developed to expand the population of patients that
respond well to immunotherapy, but research is still focused on finding options to
improve the onset of anti-tumor immunity. Immunotherapies typically fall into one of two
broad categories, enhancers and normalizers.207 Enhancers include therapies like CAR
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T cells and IL-2, whose purpose is to increase pressure on the immune system to drive
anti-tumor immunity, but do not eliminate tumor-induced immunosuppression within the
tumor microenvironment.207 On the other hand, normalizer therapies, like immune
checkpoint inhibitors, restore normal immune function and remove immune recognition
escape mechanisms.207 Although many immunotherapy strategies, especially adoptive
cell transfer, have shown positive results clinically, a key hurdle remains the immune
suppressive tumor microenvironment. Therefore, culturing T cells ex vivo in various
cytokines or pretreating patients with lymphodepleting chemotherapy prior to T cell
infusion have been used to increase the efficiency of adoptive cell transfer therapies. In
most cases, employing both enhancer and normalizer approaches simultaneously
shows the greatest potential in establishing anti-tumor immunity, and as a result,
combination therapies are being tested. Giving lymphodepleting chemotherapy to
patients prior to infusion eliminates the endogenous immune system which is thought to
enhance engraftment and survival of infused T cells by “making space.”208
Lymphodepletion is the process of using chemotherapy drugs, such as
cyclophosphamide (Cy) or fludarabine (Flu), to eliminate endogenous lymphocytes, and
has recently been used in conjunction with immunotherapies.208 Patients show
significantly better response rate when lymphodepleting chemotherapy is administered
prior to therapy.209 For example, patients with metastatic melanoma who receive
lymphodepleting chemotherapy demonstrate a higher proportion of complete responses
to tumors compared to patients who weren’t lymphodepleted prior to adoptive cell
transfer of TIL therapy.210,211 Furthermore, combination of Cy/Flu chemotherapy with
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CAR T cell therapy in patients with aggressive non-Hodgkin Lymphoma has also
showed significant increase in CAR T cell persistence and expansion, which leads to
higher clinical response rates.210,212 Lymphodepletion prior to adoptive cell transfer also
reduces or eliminates suppressive cells giving the transferred cells a more hospitable
environment to attack the tumor.209 In this case, the lymphodepletion is the normalizing
therapy while the cell therapy is the enhancer. Scientists like Steven A. Rosenberg have
also extensively observed that culturing lymphocytes, engineered or endogenous, in IL2 prior to infusion results in enhanced anti-tumor responses, especially when they’re
administered after lymphodepleting chemotherapy.106 Along the same lines, culturing T
cells in cytokines such as IL-15 or IL-7 in addition to IL-2 before they’re administered to
patients is being studies as these and other cytokines vastly improves T cell function
and longevity following adoptive transfer.213 Finally, combination immune therapies have
also been shown to improve anti-tumor results in cancer patients, especially in the case
of using checkpoint inhibitors in conjunction with other methods like cell therapy to
eliminate tumors.214 Combining immune checkpoint blockade therapy with other
conventional enhancer therapies looks to be a very strong candidate for effective
immunotherapy. PD-L1 is highly expressed on tumor cells, which causes immune
suppression in the tumor microenvironment and prohibits proper function of T cells
when they’re administered to cancer patients.215 Also, T cell exhaustion, and therefore
enhanced PD-1 expression by T cells, is commonly observed in high-mutation load
cancer types.216 CTLA-4 is also expressed on activated T cells, which commonly leads
to decreased activity of tumor-specific T cells.217 By administering T cell therapies like
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TCR/CAR T cells or TILs with immune checkpoint blockers, data suggests that infused
T cell functionality increases dramatically.1 This form of combination therapy has
demonstrated enhanced anti-tumor responses and better overall outcomes clinically as
well.216,217 Clinical data has demonstrated an objective response rate of 30% in patients
given cytotoxic T cells specific for the melanoma antigen MART-1 in combination with
the FDA-approved CTLA-4 blocker ipilimumab. Figure 13 uses this clinical example to
demonstrate the function of a combination therapy using MART-1 specific T cells and
CTLA-4 blockade.

Figure 13. Combination Therapies: Tumor-Specific T cells with Immune
Checkpoint Blockade. The immunosuppressive tumor microenvironment is partly
responsible for reduced anti-tumor immunity induction after cellular therapies. Using
checkpoint inhibitors like ipilimumab, a CTLA-4 blocker, in combination with cellular
therapies, like infusion of tumor-antigen specific T cells (shown as MART-1 specific cells
here) have been demonstrated to show enhanced clinical efficacy as compared to
singular therapy methods.
These methods of combination therapy are being employed in particularly difficult-totreat cancers, like lung cancer and pancreatic cancer, in the hopes that combining
conventional therapies can eliminate tumors and improve survival.218,219
Immunotherapies have come a long way since their inception, and through practice and
research, lots of new information regarding their use and effects have been discovered.
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The development of novel and creative immunotherapies is due in part to increased
understanding of immune responses. Elucidating precise immune mechanisms and
cellular interactions that occur within the immune system have been imperative to the
field of cancer immunotherapy, and combination therapies are a relatively new
treatment method and is a promising pathway to developing powerful and secure
therapies to fight cancer.
Concluding Remarks
The immune system is absolutely critical to protecting the human body from
pathogens and disease. Stringent selection mechanisms regulate T cell development to
ensure that endogenous T cells function properly by recognizing foreign antigens and
destroying the cells that present them. Despite the perfectly balanced homeostatic
mechanisms that the immune system employs to function effectively, there is a major
disease that the immune system is not naturally built to fight: cancer. Cancer cells
transform from normal cells and present self-antigens that T cells inherently are not
meant to recognize. Along with the innate inability of the immune system to fight cancer
cells, tumor cells also exploit immunosuppressive defense mechanisms to protect
themselves from destruction. However, the discovery of endogenous immunogenic
tumor-specific T cells was a revolutionary finding in that it gave scientists confidence
that the immune system can be turned back on with the right stimulation to fight cancer.
As a result, immunotherapy has become a strong candidate to treat many types of
cancer. From adoptive cell therapies to immune checkpoint inhibitors, immunotherapies
have been FDA-approved and are used to treat hematological malignancies and solid
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tumors, like B-cell acute lymphoblastic leukemia (B-ALL) or melanoma. Even though
there are some issues with these therapies that limit the number of patients that
respond completely, methods to enhance the efficacy of these treatments clinically are
being researched and elucidated. While immunotherapy as a discipline is consistently
being propelled forward by improving upon current methods and approaches,
discovering new and creative ways to induce anti-tumor immunity in patients are critical
to driving science forward.
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